【导读】首只超 21 亿元浮费产品提前结募 中国基金报记者 曹雯璟 首只，来了！ 8 月 12 日，中欧核心智选混合基金发布公告称，募集截止日由 8 月 15 日提前至 8 月 12 日， 8 月 13 日（含当日）起不再接受投资者 的认购申请。 记者从业内了解到，中欧核心智选混合基金首募规模超 21 亿元，这也是首只募集规模超 21 亿元的浮费产品。从销售渠道来看，银行仍占 据主导地位， 其中兴业银行贡献了绝大多数的销售规模 。 8 月 12 日， 中欧核心智选混合基金 发布提前结募公告。据了解，该基金是行业首只募集规模超 21 亿元的新型浮动费率基金产品（以下 简称浮费产品）。 至此，第二批新型浮动费率基金中，已有两 只产品宣布提前结束募集。 首只超 21 亿元浮费产品提前结募 除了上述三只产品，国泰优质核心混合已于 8 月 11 日正式发行，募集份额上限为 30 亿份。该基金业绩比较基准为沪深 300 指数收益率 ×60%+ 中证港股通综合指数收益率（经估值汇率调整） ×20%+ 中债新综合全价（总值）指数收益率 ×20% 。 首批 26 只新型浮费基金已经建仓 多数正收益 业内人士表示，浮动费率基金本 ...

Core Insights - A total of 19 public funds have launched their initial fundraising on August 4, including three products from the second batch of new floating-rate funds: E Fund Value Return Mixed, China Europe Core Select Mixed, and Jianxin Medical Innovation Stock [1] Fund Details - China Europe Core Select Mixed is set to end its fundraising on August 15, E Fund Value Return Mixed on August 20, and Jianxin Medical Innovation Stock on August 22 [1] - Jianxin Medical Innovation has a fundraising cap of 3 billion yuan [1] Fund Management - E Fund Value Return is managed by Tang Bolun, Jianxin Medical Innovation by Ma Muqing, and China Europe Core Select by Zhang Cong and Song Ting [1] Fund Approval and Themes - The second batch of new floating-rate funds was approved on July 24, covering various industry themes such as pharmaceuticals, manufacturing, and high-end equipment, along with initiator funds [1] - Among the new products, there are 2 stock-type funds and 10 equity-mixed funds, including: Invesco Great Wall High-end Equipment Stock, Jianxin Medical Innovation Stock, Bank of China Quality Emerging Mixed, Ping An Research-Driven Mixed, Southern Ruijing Mixed, Oriental Red Medical Innovation Mixed, E Fund Value Return Mixed, Huatai-PB Manufacturing Theme Mixed, Guotai Quality Core Mixed, China Europe Core Select Mixed, and Morgan Huikai Growth Mixed [1]

Core Viewpoint - The approval of a second batch of 12 new model floating management fee rate funds marks an expansion in the market, with a focus on industry-specific themes alongside general market selection products [1][2]. Group 1: Fund Approval and Structure - The newly approved funds include thematic products in high-end equipment, pharmaceuticals, and manufacturing, expanding beyond the first batch which focused solely on general market selection [1]. - Fund managers such as Guotai Fund, Huatai-PB Fund, Morgan Asset Management, and others are participating for the first time, while some like China Europe Fund and Oriental Red Asset Management are reapplying after the first batch [1]. - The floating management fee structure links fees to fund performance against a benchmark, with rates set at 1.2% for the baseline, 1.5% for an upgrade, and 0.6% for a downgrade, aligning the interests of fund managers and investors [1]. Group 2: Differentiation and Strategy - Huatai-PB Fund and Oriental Red Asset Management have implemented differentiated thresholds for their products, raising the downgrade threshold to 2 percentage points below the benchmark, enhancing performance accountability [2]. - The new model aims for a "one client, one share" fee structure, allowing for personalized fee arrangements, which is a shift from previous models that linked fees to overall fund performance [2]. - The introduction of thematic funds indicates a strategic shift from broad market selection to more specialized investment strategies, catering to diverse investor needs [2]. Group 3: Investment Opportunities - The Huatai-PB Manufacturing Theme Mixed Fund exemplifies the potential in China's manufacturing sector, which is undergoing a transformation towards high-end and intelligent manufacturing, presenting numerous investment opportunities [3]. - Investors are advised to consider the investment capabilities and philosophies of fund companies and managers, as well as specific details in fund contracts regarding fee structures and performance benchmarks, to align with their risk tolerance and investment goals [3].

Core Viewpoint - The second batch of 11 floating fee rate new funds has been submitted for approval, expanding from the first batch of 26 funds, and includes both broad market selection products and industry-specific thematic products, particularly in sectors like pharmaceuticals, high-end equipment, and manufacturing [1][2]. Group 1: Fund Characteristics - The new floating fee rate funds are designed to meet investor demand for quality technology investment tools and leverage the research team's expertise in the technology growth sector [1][6]. - The second batch includes a diverse range of products, moving from broad market strategies to more specialized thematic strategies, indicating a richer variety of offerings to cater to different investor preferences [2][3]. - The management fee structure remains at three tiers: 1.2% (benchmark), 1.5% (upward adjustment), and 0.6% (downward adjustment), with specific conditions for fee application based on fund performance relative to benchmarks [2][3]. Group 2: Industry Focus - High-end equipment and pharmaceuticals are highlighted as key sectors for the new thematic funds, with high-end equipment being a core support of the modern industrial system and a significant part of technology investment [6]. - The pharmaceutical sector, particularly the innovative drug segment, is experiencing rapid revenue growth, with companies poised to enter international markets, indicating substantial future opportunities [6]. - The focus on biotechnology companies with global market potential and traditional pharmaceutical companies undergoing successful transformations is emphasized as a strategic investment direction [6].